Clene Nanomedicine

Clene is launching a new class of neurotherapeutics called nanocatalysts. Their nanocatalysts work across multiple cell types to enhance various bioenergetic processes that can effectively treat many different diseases. This novel, broad-spectrum approach represents a revolutionary shift in the pharmacological treatment of diseases. On December 31, 2020, Clene Nanomedicine merged with Tottenham Acquisition I Limited, and the combined public company operates under the name Clene Inc.